Canaccord lowered the firm’s price target on Exact Sciences to $90 from $100 and keeps a Buy rating on the shares. The firm said its target decrease is driven by lower and more realistic long-term margin assumptions after the company reported 4Q23 results that were essentially in line with its preliminary results announced in early January.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXAS:
- LLY, CVS, EXAS: Which Strong-Buy-Rated Healthcare Stock Is the Better Buy?
- Is EXAS a Buy, Before Earnings?
- BIIB, ZTS, EXAS: Which “Strong Buy” Healthcare Stock is Best?
- Exact Sciences (NASDAQ:EXAS) Announces Strong Preliminary Q4 Results and CFO Transition
- Exact Sciences says Jeff Elliott stepping down as executive VP, CFO
